Subtyping of Parkinson’s Disease by Longitudinal Trajectories of Levodopa Equivalent Daily Dose
Heterogeneity is noted in the increase in the use of antiparkinsonian medications, which is driven by changes in motor phenotype, medication efficacy, and the occurrence of PD-relevant milestones. Subtyping patients on the basis of LEDD trajectories may provide insight into clinical heterogeneity for future research on individualized treatment strategies for patients with PD.
Authors
- So Hoon Yoon (ORCID: https://orcid.org/0000-0003-3265-3965)
- Sung Woo Kang (ORCID: https://orcid.org/0000-0001-9791-6899)
- Young‐gun Lee (ORCID: https://orcid.org/0000-0003-0460-455X)
- Mincheol Park (ORCID: https://orcid.org/0000-0003-2714-7494)
- Kyoungwon Paik
Institutions
- Korea University Medical Center (KR)
- Inje University Ilsan Paik Hospital (KR)
- Sungae Hospital (KR)
- National Health Insurance Service Ilsan Hospital (KR)
- Catholic Kwandong University International St. Mary's Hospital (KR)
- National Health Insurance Service (KR)
- Korea University (JP)
- Hanyang University (KR)
Publication Details
- Journal
- Journal of Movement Disorders
- Published
- 2025-07-21
- DOI
- https://doi.org/10.14802/jmd.25099
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Michael J. Fox Foundation for Parkinson's Research
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Neurocrine Biosciences
- Verily Life Sciences
- Voyager Therapeutics
- Servier
- H. Lundbeck A/S
- Genentech
- Allergan
- Sanofi Genzyme
- Avid Radiopharmaceuticals